PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group

Purpose To determine the real-world incidence and predictive factors for venous and arterial thromboembolic events (VTE/AT) in ovarian cancer patients treated with poly-(ADP-ribose) polymerase inhibitors (iPARP). Methods/patients A multicenter retrospective study involving 329 ovarian cancer patient...

Descripción completa

Detalles Bibliográficos
Autores: Cánovas, MS, Robles, JL, Verdejo, FJG, Lavin, DC, Olivares, H, Fernández, AG, Salvans, EC, Verduguez, TQ, Coloma, CS, Garay, DF, Cumplido, JD, Pérez, AIF, Bagué, AC, Muñoz, FJT, López, RG, Marin, AM, Martín, AJM
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p19384
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/19384
Access Level:acceso abierto
Palabra clave:PARP inhibitors
Cancer-related thrombosis
Ovarian cancer
id ES_ea1c4b4bd13f2e5f66ac176d93af009a
oai_identifier_str oai:fisabio.fundanetsuite.com:p19384
network_acronym_str ES
network_name_str España
repository_id_str
spelling PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer groupCánovas, MSRobles, JLVerdejo, FJGLavin, DCOlivares, HFernández, AGSalvans, ECVerduguez, TQColoma, CSGaray, DFCumplido, JDPérez, AIFBagué, ACMuñoz, FJTLópez, RGMarin, AMMartín, AJMPARP inhibitorsCancer-related thrombosisOvarian cancerPurpose To determine the real-world incidence and predictive factors for venous and arterial thromboembolic events (VTE/AT) in ovarian cancer patients treated with poly-(ADP-ribose) polymerase inhibitors (iPARP). Methods/patients A multicenter retrospective study involving 329 ovarian cancer patients who initiated iPARP treatment between January 2015 and December 2022. The primary outcome was the incidence of VTE/AT. Secondary outcomes included predictive factors for thrombosis and the impact of thrombosis on overall survival (OS). Data were analyzed using logistic regression and Kaplan-Meier survival analysis. Results The incidence of VTE/AT was 4.9% (16/329). BRCA2 mutations were significantly more prevalent among patients who developed VTE/AT (56.3% vs. 19.2%; p < 0.001). Combined treatment with bevacizumab was significantly associated with a decreased risk of thrombosis (OR: 0.262; 95% CI: 0.095-0.724; p = 0.010). No statistically significant differences were observed in the median OS between patients who experienced VTE/ATE (63 months) and those who did not (47 months), with a p value of 0.876. Conclusions BRCA2 mutations could be a significant predictor for VTE/AT among ovarian cancer patients treated with iPARP. Concomitant treatment with bevacizumab may offer protection against thrombotic events, although a concomitant bias cannot be ruled out. These findings may be of interest when designing future clinical trials in the field of thromboprophylaxis.SPRINGER INT PUBL AG2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/19384Clinical & Translational OncologyISSN: 1699048XISSNe: 16993055reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p193842026-06-11T12:45:17Z
dc.title.none.fl_str_mv PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group
title PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group
spellingShingle PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group
Cánovas, MS
PARP inhibitors
Cancer-related thrombosis
Ovarian cancer
title_short PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group
title_full PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group
title_fullStr PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group
title_full_unstemmed PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group
title_sort PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group
dc.creator.none.fl_str_mv Cánovas, MS
Robles, JL
Verdejo, FJG
Lavin, DC
Olivares, H
Fernández, AG
Salvans, EC
Verduguez, TQ
Coloma, CS
Garay, DF
Cumplido, JD
Pérez, AIF
Bagué, AC
Muñoz, FJT
López, RG
Marin, AM
Martín, AJM
author Cánovas, MS
author_facet Cánovas, MS
Robles, JL
Verdejo, FJG
Lavin, DC
Olivares, H
Fernández, AG
Salvans, EC
Verduguez, TQ
Coloma, CS
Garay, DF
Cumplido, JD
Pérez, AIF
Bagué, AC
Muñoz, FJT
López, RG
Marin, AM
Martín, AJM
author_role author
author2 Robles, JL
Verdejo, FJG
Lavin, DC
Olivares, H
Fernández, AG
Salvans, EC
Verduguez, TQ
Coloma, CS
Garay, DF
Cumplido, JD
Pérez, AIF
Bagué, AC
Muñoz, FJT
López, RG
Marin, AM
Martín, AJM
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv PARP inhibitors
Cancer-related thrombosis
Ovarian cancer
topic PARP inhibitors
Cancer-related thrombosis
Ovarian cancer
description Purpose To determine the real-world incidence and predictive factors for venous and arterial thromboembolic events (VTE/AT) in ovarian cancer patients treated with poly-(ADP-ribose) polymerase inhibitors (iPARP). Methods/patients A multicenter retrospective study involving 329 ovarian cancer patients who initiated iPARP treatment between January 2015 and December 2022. The primary outcome was the incidence of VTE/AT. Secondary outcomes included predictive factors for thrombosis and the impact of thrombosis on overall survival (OS). Data were analyzed using logistic regression and Kaplan-Meier survival analysis. Results The incidence of VTE/AT was 4.9% (16/329). BRCA2 mutations were significantly more prevalent among patients who developed VTE/AT (56.3% vs. 19.2%; p < 0.001). Combined treatment with bevacizumab was significantly associated with a decreased risk of thrombosis (OR: 0.262; 95% CI: 0.095-0.724; p = 0.010). No statistically significant differences were observed in the median OS between patients who experienced VTE/ATE (63 months) and those who did not (47 months), with a p value of 0.876. Conclusions BRCA2 mutations could be a significant predictor for VTE/AT among ovarian cancer patients treated with iPARP. Concomitant treatment with bevacizumab may offer protection against thrombotic events, although a concomitant bias cannot be ruled out. These findings may be of interest when designing future clinical trials in the field of thromboprophylaxis.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/19384
url https://fisabio.portalinvestigacion.com/publicaciones/19384
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SPRINGER INT PUBL AG
publisher.none.fl_str_mv SPRINGER INT PUBL AG
dc.source.none.fl_str_mv Clinical & Translational Oncology
ISSN: 1699048X
ISSNe: 16993055
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423111041974272
score 15,812455

Similares en LA Referencia